337 related articles for article (PubMed ID: 15654581)
1. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
[TBL] [Abstract][Full Text] [Related]
2. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
JAMA; 2002 May 22-29; 287(20):2668-76. PubMed ID: 12020302
[TBL] [Abstract][Full Text] [Related]
3. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
[TBL] [Abstract][Full Text] [Related]
4. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
[TBL] [Abstract][Full Text] [Related]
5. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
6. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women.
Utian WH; Gass ML; Pickar JH
Menopause; 2004; 11(3):306-14. PubMed ID: 15167310
[TBL] [Abstract][Full Text] [Related]
7. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
8. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
ThiƩbaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
Lindsay R; Gallagher JC; Kagan R; Pickar JH; Constantine G
Fertil Steril; 2009 Sep; 92(3):1045-1052. PubMed ID: 19635616
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
11. Effects on bone of oral hormone replacement therapy initiated 2 years after ovariectomy in young adult monkeys.
Jayo MJ; Register TC; Carlson CS
Bone; 1998 Oct; 23(4):361-6. PubMed ID: 9763148
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
Gutteridge DH; Holzherr ML; Retallack RW; Price RI; Will RK; Dhaliwal SS; Faulkner DL; Stewart GO; Stuckey BG; Prince RL; Criddle RA; Drury PJ; Tran L; Bhagat CI; Kent GN; Jamrozik K
Calcif Tissue Int; 2003 Jul; 73(1):33-43. PubMed ID: 14506952
[TBL] [Abstract][Full Text] [Related]
13. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
Arrenbrecht S; Boermans AJ
Osteoporos Int; 2002; 13(2):176-83. PubMed ID: 11908492
[TBL] [Abstract][Full Text] [Related]
14. Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study.
Ausmanas MK; Holinka CF; Ling YS; Christiansen C
Climacteric; 2007 Aug; 10(4):306-13. PubMed ID: 17653957
[TBL] [Abstract][Full Text] [Related]
15. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
[TBL] [Abstract][Full Text] [Related]
16. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
Bhattoa HP; Bettembuk P; Balogh A; Szegedi G; Kiss E
Osteoporos Int; 2004 May; 15(5):396-404. PubMed ID: 14676992
[TBL] [Abstract][Full Text] [Related]
17. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
Cauley JA; Robbins J; Chen Z; Cummings SR; Jackson RD; LaCroix AZ; LeBoff M; Lewis CE; McGowan J; Neuner J; Pettinger M; Stefanick ML; Wactawski-Wende J; Watts NB;
JAMA; 2003 Oct; 290(13):1729-38. PubMed ID: 14519707
[TBL] [Abstract][Full Text] [Related]
18. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial.
Civitelli R; Pilgram TK; Dotson M; Muckerman J; Lewandowski N; Armamento-Villareal R; Yokoyama-Crothers N; Kardaris EE; Hauser J; Cohen S; Hildebolt CF
Arch Intern Med; 2002 Jun; 162(12):1409-15. PubMed ID: 12076241
[TBL] [Abstract][Full Text] [Related]
19. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens.
Heikkinen J; Vaheri R; Kainulainen P; Timonen U
Osteoporos Int; 2000; 11(11):929-37. PubMed ID: 11193245
[TBL] [Abstract][Full Text] [Related]
20. Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial.
Yoon BK; Lee DY; Park MC; Cho SH; Park HM; Choi YM
J Korean Med Sci; 2017 Jun; 32(6):992-998. PubMed ID: 28480658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]